(9 years, 1 month ago)
Commons ChamberThe hon. Gentleman makes an excellent point. Genome editing is the latest in a suite of technologies that is rapidly emerging in genomics. Through the Genomics England programme, we are actively supporting those tools and intermediate technologies, and through the accelerated access review that I have launched, we are looking to harness those breakthroughs to support new treatments and new flexibilities for the National Institute for Health and Care Excellence and NHS England on targeted treatments.
8. What progress he has made on implementing a new contract for junior doctors; and if he will make a statement.
(10 years, 3 months ago)
Commons ChamberT5. As my hon. Friend knows, Plymouth is the host of the Peninsula medical school. In the light of the Ashya King case, in which Ashya’s parents had to flee to another country to get treatment for him that was not available in the UK, what plans does he have to accelerate research into new drug and medical technology?
My hon. Friend makes an important point. That case highlights the importance of Britain remaining at the forefront of medical innovation. To that end, we have set out our groundbreaking 10-year life science strategy, and I pay tribute to my predecessor, my right hon. Friend the Member for Havant (Mr Willetts), for that. My central mission in this new role is to ensure that Britain leads the world and is the best place in the world to develop 21st century medicines and health care technologies.